For GA Treatment, the Earlier the Better
Key Study Findings
Researchers analyzed 782 patients transitioning from the two-year OAKS/DERBY trials into the three-year GALE extension study.
Superior Tissue Preservation: Patients who started treatment immediately (early group) preserved 3.87 mm² of retinal tissue over five years. Those who started two years late (delayed group) preserved only 1.93 mm².
Reduced Growth Rates: In nonsubfoveal GA, monthly injections reduced lesion growth by 33% compared to the sham group.
Disease Delay: Continuous five-year therapy delayed the progression of nonsubfoveal GA by approximately 16.5 to 18.5 months.
Safety Profile: The treatment remained well-tolerated over five years. Rare instances of retinal vasculitis occurred in fewer than 1 in 4,000 cases, consistent with earlier trial data.
Conclusion
The study concludes that
Comments
Post a Comment
Leave a Comment or Question: